PD-1
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
... Three tissue microarray (TMA) slides were used to evaluate the expression patterns of the PD-1 axis. One was con- structed using samples acquired from the Musculoskeletal Tumor Center, Peking University ...
13
Macrophage PD L1 strikes back: PD 1/PD L1 interaction drives macrophages toward regulatory subsets
... whether PD-1 and PD-L1 interaction be- tween macrophages and T cells alters macrophage ...for PD-1/PD-L1 engagement inducing a regulatory profile in macro- ...from PD- L1 ...
11
T cell Bim levels reflect responses to anti–PD-1 cancer therapy
... whether Bim could be used as a noninvasive monitoring or predictive biomarker to evaluate T cell responses in patients with cancer undergoing treatment with an anti–PD-1 monoclonal antibody. Among the 38 ...
15
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
... contrast, PD-1 is primarily to inhibit activated T-cell function via its interaction with PD-L1 and ...that PD-1 ligation inhibited PI3K activity and downstream AKT activation, whereas ...
14
Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment
... of PD-1 and its ligands, PD-L1 and PD-L2, was assessed by flow cytometry on peripheral blood mononuclear cells (PBMC) and compared to patients who had discontinued nivolumab therapy without ...
5
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
... of PD-1, and natural killer T-cells express low levels of ...that PD-L1 is expressed at high levels by activated CD4+T cells ...Although PD- 1 was not preferentially expressed in pro-B ...
6
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
... of PD- 1 was found to be increased on T cells of older adults and its blockade did not restore T cell activity to the same extent as in younger adults [22–24] Our under- standing of the efficacy of ...
8
Contribution of NK cells to immunotherapy mediated by PD 1/PD L1 blockade
... that PD-1 can be expressed on human NK cells has recently emerged in several cancer indications, including Hodg- kin’s lymphoma (40–44), but mechanistic in vivo studies examin- ing whether and how ...
16
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
... on PD-1 expression have focused on immune cells, rendering its potential expression and functions in tumor cells remaining largely ...intrinsic PD-1 signaling in neoplastic cells, the effect ...
13
Original Article Expression level and clinical significance of PD-1, MMP-2 and SE-Cad in patients with acute myeloid leukemia
... Abstract: Objective: We aimed to research the expression level andthe significance of related clinical application of programmed death-1 (PD-1), matrix metalloproteinase 2 (MMP-2), soluble Ecadherin ...
10
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
... with PD-1 blockades may be a potential strategy to overcome the immunosuppressive context ...with PD-1 checkpoint blockades also achieved OS benefits in glioblastoma mouse models via directly ...
13
Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
... TCGA also recently reported the genomic characterisation of oesophageal carcinoma (22). As one would expect, squamous cell carcinoma (SCC) and adenocarcinoma were molecularly distinct. Oesophageal adenocarcinoma strongly ...
42
Anti–PD 1/PD L1 therapy of human cancer: past, present, and future
... mice, PD-L1 KO mice do not spon- taneously develop massive infiltration of inflammatory cells in normal organs, and these mice have an overall normal life span ...However, PD-1 KO mice do ...
9
CD84 regulates PD 1/PD L1 expression and function in chronic lymphocytic leukemia
... ligand 1/programmed cell death 1 (PD-L1/PD-1) ...upregulates PD-L1 expression on CLL cells and in their microenvironment and PD-1 expression on T ...
15
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
... human PD-1 with a stabilizing hinge region mutation that is resistant to the exchange of IgG4 ...cohorts 1 and ...(cohort 1) were randomized 1:1 to NIVO 3 mg/kg (N3) every 2 ...
10
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy
... that PD-1 immunotherapy could activate T cells in the TDLNs, which may contribute to the antitumor ...of PD-1 treat- ment, we evaluated the actual contribution of TDLNs in therapeutic ...16). ...
7
Checkpoint molecule PD-1-assisted CD8<sup>+</sup> T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
... Continuous slides of formalin-fixed, paraffin-embedded tissues were used for immunohistochemical staining. The slides were heated at 60°C for 2 hours, dewaxed in xylene, and dehydrated by a gradient concentration of ...
13
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
... A PD-1 blockade is mainly administered for patients with advanced esophageal cancer, including patients showing first-line drug resistant esophageal cancer, or local- ized progression and advanced ...
21
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
... (PD-Ls) 1 and 2, are expressed by a variety of cells including cancer cells, suggesting a role for these molecules as an immune evasion ...the PD-1-PD-L signaling axis has recently been ...
15
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
... death- 1 (PD-1) and the ligand 1 (PD-L1) has opened the door to the modern era of cancer immunotherapy [12, ...of PD-L1 which leads to anergy of cytotoxic T cells upon ...
8